drugset / Trial / NCT01970033
Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to evaluate the efficacy and safety of SP2086 as monotherapy in patients with Type 2 Diabetes Mellitus in Metformin monotherapy Who Have Inadequate Glycemic Control treated with diet and exercise for 3 months
Timeline
- Start
- 2012-12
- Primary completion
- 2014-01
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retagliptin | Small molecule | 50 mg | — |
| Subject | Retagliptin | Small molecule | 100 mg | — |